Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · February 15, 2024

Sustained Remission Without Corticosteroids in Patients With Pemphigus Treated With Rituximab as First-Line Therapy

JAMA Dermatology


Additional Info

JAMA Dermatology
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial
JAMA Dermatol 2024 Jan 24;[EPub Ahead of Print], B Tedbirt, M Maho-Vaillant, E Houivet, C Mignard, ML Golinski, S Calbo, C Prost-Squarcioni, B Labeille, C Picard-Dahan, G Chaby, MA Richard, E Tancrede-Bohin, S Duvert-Lehembre, E Delaporte, P Bernard, F Caux, M Alexandre, P Musette, S Ingen-Housz-Oro, P Vabres, G Quereux, A Dupuy, S Debarbieux, M Avenel-Audran, M D'Incan, C Bédane, N Bénéton, D Jullien, N Dupin, L Misery, L Machet, M Beylot-Barry, O Dereure, B Sassolas, J Benichou, P Joly, V Hébert

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading